Brief report
Glucocorticoids alone versus tocilizumab alone or glucocorticoids plus tocilizumab in patients with severe SARS-CoV-2 pneumonia and mild inflammation
Glucocorticoides solos versus tocilizumab solo o glucocorticoides más tocilizumab en pacientes con neumonía grave por SARS-CoV-2 e inflamación moderada
Ismael Francisco Aomar-Millána,
,◊, Juan Salvatierrab,◊, Úrsula Torres-Parejoc, María Nuñez-Nuñezd,e, José Hernández-Queroe, Francisco Anguita-Santose
a Servicio de Medicina Interna, Hospital Universitario San Cecilio, Granada, Spain
b Servicio de Reumatología, Hospital Universitario San Cecilio, Granada, Spain
c Departamento de Estadística, Universidad de Granada, Granada, Spain
d Servicio de Farmacia, Hospital Universitario San Cecilio, Granada, Spain
e Servicio de Enfermedades Infecciosas, Hospital Universitario San Cecilio, Granada, Spain
Read
106
Timeswas read the article
0
Total PDF
106
Total HTML
| Year/Month | Html | Total | |
|---|---|---|---|
| 2024 November | 2 | 0 | 2 |
| 2024 October | 2 | 0 | 2 |
| 2024 August | 3 | 0 | 3 |
| 2024 July | 5 | 0 | 5 |
| 2024 June | 1 | 0 | 1 |
| 2024 May | 3 | 0 | 3 |
| 2024 April | 1 | 0 | 1 |
| 2024 March | 2 | 0 | 2 |
| 2024 February | 3 | 0 | 3 |
| 2024 January | 1 | 0 | 1 |
| 2023 December | 5 | 0 | 5 |
| 2023 November | 3 | 0 | 3 |
| 2023 October | 3 | 0 | 3 |
| 2023 September | 6 | 0 | 6 |
| 2023 August | 3 | 0 | 3 |
| 2023 June | 1 | 0 | 1 |
| 2023 May | 2 | 0 | 2 |
| 2023 April | 2 | 0 | 2 |
| 2023 March | 1 | 0 | 1 |
| 2023 February | 3 | 0 | 3 |
| 2023 January | 2 | 0 | 2 |
| 2022 December | 2 | 0 | 2 |
| 2022 November | 1 | 0 | 1 |
| 2022 October | 4 | 0 | 4 |
| 2022 September | 2 | 0 | 2 |
| 2022 August | 2 | 0 | 2 |
| 2022 July | 4 | 0 | 4 |
| 2022 June | 3 | 0 | 3 |
| 2022 May | 6 | 0 | 6 |
| 2022 April | 8 | 0 | 8 |
| 2022 March | 3 | 0 | 3 |
| 2022 February | 3 | 0 | 3 |
| 2022 January | 12 | 0 | 12 |
| 2021 December | 1 | 0 | 1 |
| 2021 November | 1 | 0 | 1 |
Show all
